📌 At a glance:
- FY25 PAT: ₹566 crore (–15% YoY)
- FY25 Revenue: ₹2,479 crore (–2.6%)
- Q4 PAT: ₹126 crore (–21% YoY)
- CMP: ₹4,890.00 (+9.44% today)
🧬 About the Company
Pfizer Ltd is the Indian arm of the global pharma giant. It operates primarily in branded formulations including vaccines, anti-infectives,
pain management, and cardiology. Unlike its global parent, it doesn’t manufacture the COVID vaccine in India.
👨⚕️ KMP
- MD: Meenakshi Nevatia
📊 FY25 Financial Summary
| Metric | FY25 | FY24 | YoY Change |
|---|---|---|---|
| Revenue | ₹2,479 cr | ₹2,545 cr | –2.6% |
| PAT | ₹566 cr | ₹665 cr | –15% |
| Q4 PAT | ₹126 cr | ₹160 cr | –21% |
🩺 What’s Going On?
- Revenue
To Read Full 16 Point ArticleBecome a member